Thyroid hormones (TH) 1 are amino acid derivatives. Owing to their zwitter-ionic nature, TH and their derivatives require transmembrane transporters to mediate their translocation across the plasma membrane (1). Several classes of transmembrane transporter proteins of the major facilitator superfamily (MFS) are capable of TH transport: organic anion transporters two and three (Oatp2 and Oatp3) were the first TH transporters cloned (2). Later, L-type amino acid transporters (Lat1, Lat2) (3) and monocarboxylate transporters eight and ten (MCT8 and MCT10) were shown to transport TH (4;5). Among these transporters, only MCT8 is specific for TH. Mutations in MCT8/SLC16A2 lead to severe psychomotor retardation and TH abnormalities in humans (6;7), including the Allan-Herndon-Dudley Syndrome (8). Patients suffering from mutations in MCT8 are characterized by high serum T 3 values associated with low T 4 and inappropriately normal TSH. This clinical phenotype suggested that MCT8 is involved in pituitary feedback control of http://www.jbc.org/cgi
Monocarboxylate transporter 8 (MCT8, SLC16A2) is a thyroid hormone (TH) transmembrane transport protein mutated in
Allan-Herndon-Dudley syndrome, a severe Xlinked psychomotor retardation. The neurological and endocrine phenotypes of patients deficient in MCT8 function underscore the physiological significance of carriermediated TH transmembrane transport. MCT8 belongs to the major facilitator superfamily of 12 transmembrane spanning proteins and mediates energy-independent bidirectional transport of iodothyronines across the plasma membrane. Structural information is lacking for all TH transmembrane transporters. In order to gain insight into structure-function relations in TH transport, we chose human MCT8 as paradigm. We systematically performed conventional and liquid chromatographytandem mass spectrometry-based uptake measurements into MCT8-transfected cells using a large number of compounds structurally related to iodothyronines. We found that human MCT8 is specific for Liodothyronines and requires at least one iodine atom per aromatic ring. Neither thyronamines, decarboxylated metabolites of iodothyronines, nor triiodothyroacetic acid and tertraiodothyroacetic acid, TH derivatives lacking both chiral center and amino group, are substrates for MCT8. The polyphenolic flavonoids naringenin and F21388, potent competitors for TH binding at transthyretin, did not inhibit T 3 transport, suggesting that MCT8 can discriminate its ligand better than transthyretin. Bioinformatic studies and a first molecular homology model of MCT8 suggested amino acids potentially involved in substrate interaction. Indeed, alanine mutation of either Arg445 (helix 8) or Asp498 (helix 10) abrogated T 3 transport activity of MCT8, supporting their predicted role in substrate recognition. The MCT8 model allows to rationalize potential interactions of amino acids including those mutated in patients with Allan-HerndonDudley syndrome.
Thyroid hormones (TH) 1 are amino acid derivatives. Owing to their zwitter-ionic nature, TH and their derivatives require transmembrane transporters to mediate their translocation across the plasma membrane (1) . Several classes of transmembrane transporter proteins of the major facilitator superfamily (MFS) are capable of TH transport: organic anion transporters two and three (Oatp2 and Oatp3) were the first TH transporters cloned (2) . Later, L-type amino acid transporters (Lat1, Lat2) (3) and monocarboxylate transporters eight and ten (MCT8 and MCT10) were shown to transport TH (4;5) . Among these transporters, only MCT8 is specific for TH. Mutations in MCT8/SLC16A2 lead to severe psychomotor retardation and TH abnormalities in humans (6;7), including the Allan-Herndon-Dudley Syndrome (8) . Patients suffering from mutations in MCT8 are characterized by high serum T 3 values associated with low T 4 and inappropriately normal TSH. This clinical phenotype suggested that MCT8 is involved in pituitary feedback control of the TH axis. Sensitivity to TH thus depends on the expression of TH transporter molecules. Expression of MCT8 in the mouse brain (9) supported the idea that TH import into neurons may be affected in patients afflicted with the Allan-Herndon-Dudley syndrome. Mice deficient in MCT8 recapitulate the disturbed serum thyroid hormone parameters (10;11), but exhibit only mild neurological abnormalities (12) . Murine neurons are apparently protected from the lack of MCT8 by expression of alternative T 3 transporters such as Lat2, which is not present in human developing neurons (12) . More than two-dozen mutations in MCT8 have been identified in human patients (13) . Genotypephenotype correlations suggested that most missense mutations cause a complete loss-offunction phenotype in patients. A comparison of 12 missense mutants revealed that pathogenic MCT8 mutations may affect expression, surface translocation or specifically the substrate transport mechanism (14) . Possibly, homodimerization may also play role which we currently do not understand (15;16) . To our knowledge, no data are yet available relating structural features and transport mechanism of MCT8. Our goal in this study was to obtain new functional and structural insights in the complex system of substrate binding and transport. Systematic analysis of substrate molecules for MCT8-mediated cellular uptake revealed several structural determinants for substrate recognition by MCT8: an L-amino acid side chain and at least an iodine substitution in the 3 positions of both aromatic rings of the thyronine moiety. We also designed a homology model of human MCT8 to identify amino acids potentially involved in substrate recognition. Strikingly, mutations of charged amino acids predicted to interact with substrate disrupted T 3 import into cells. Thus, functional data support the first predictions from our structural MCT8 model.
EXPERIMENTAL PROCEDURES

Site-directed mutagenesis and stable cell lines
Mutations were introduced into human MCT8 by overlap extension PCR with the following primers (mutated bases in bold-face) R445A-fwd 5`-CAGGCCTTGGGGCTCTTGTGTCAGGCCAC-3`, R445A-rev 5`-GTGGCCTGACACAAGAGC   CCCAAGGCCTG-3`, D498A-fwd 5`-CTGGGCC  TTTGCGCCGGCTTCTTCATCAC-3`  and  D498A-rev 5`-GTGATGAAGAAGCCGGCGCA  AAGGCCCAG-3`. Plasmids were stably transfected into MDCK1 cells as described previously (14) . T 3 uptake assays One day before the experiments, 200,000 cells per well were seeded into 12-well plates.
125 I-T 3 (Perkin Elmer) was purified from iodide ions by adsorption chromatography and finally resuspended in DMEM-F12 (1:1) without serum (14) . For competitive inhibition studies, cells were exposed to 10 nM 125 I-T 3 tracer in medium for three minutes in the presence or not of 10 µM of test compound (1 mM for aromatic amino acids and BSP), medium was removed and radioactivity associated with the cells determined (supplemental Fig. S2 ). Iodothyronines and related compounds were first dissolved in DMSO (1000-fold final concentration), and then in medium. Aromatic amino acids were dissolved in uptake buffer (125 mM NaCl, 5 The detection was performed using positive electrospray ionization (ESI+) for T 3 and T 3 AM and negative electrospray ionization (ESI-) for TRIAC in the selected reaction monitoring (SRM) mode. The mass spectrometric working parameters were: TurboIon spray voltage (IS): 5500 V, curtain gas (CUR): 30 psi, collision gas (CAD): 5 psi, nebulizer gas (GS1): 60 psi, heater gas (GS2): 50 psi, entrance potential (EP): 10 V, source temperature: 400 °C, dwell time: 90 ms. Chromatographic separation of all substances was achieved using a Synergi Polar-RP 80-Å column (150 x 2 mm; Phenomenex, Aschaffenburg, Germany) and an analytical Guard Cartridge System (4.0 mm x 2.0 mm, Phenomenex, Aschaffenburg, Germany) using a gradient elution program at a flow rate of 300 µl/min. Simultaneous detection of all substances in the same biological sample was performed using a modified LC-MS/MS method as described before (18) . With the 4000QTRAP triple-quadrupole tandem mass spectrometer we reduced the time per run to 25 min using a gradient elution program: 0-2 min, 2% B; 2-12 min, 40% B; 12-15 min, 60% B; 15-15.5 min, 90% B; 15.5-16.5 min, 90% B; 16.5-17 min, 2% B; 17-19.95 min, 2% B. The device-specific mass spectrometric parameters for analytes are presented in table 1. Data processing was performed using Bio Analyst version 1.5. Software (Applied Biosystems, Darmstadt, Germany). Liquid-liquid extraction of all compounds for LC-MS/MS analysis was performed as described previously (17) . For LC-
MS/MS analysis 4 pmol deuterated 3-T 1 AM-d 4 was used as internal standard (IS).
Surface biotinylation and Western blotting
Surface biotinylation was performed on MDCK1 cells as previously described (14) . Briefly, equal amounts of 5 µg of biotinylated protein (or 80 µg of total cellular protein fraction) were separated on SDS gels, transferred onto nitrocellulose membranes, and probed with an MCT8 antibody (Atlas, Stockholm, Sweden). An antibody directed against β-actin (Rockland, Gilbertsville, USA) was used for loading control. Every experiment was performed at least twice with similar results. Bioinformatics and molecular homology modeling All amino acid sequence alignments ( Fig.1 and supplemental Fig. S1 ) were produced using a combination of automatic and manual procedures. For automatic alignments, ClustalW (19) software was applied with the Blossum62 amino acid similarity matrix. Few manual refinements were performed including Gap-introduction at loop regions, but not in transmembrane helices. Alignments were produced with the BioEdit software package (http://www.mbio.ncsu.edu).
Human MCT family members were aligned to analyze shared and divergent features in amino acid composition (Fig. 1) . The potential dimensions of transmembrane helices (TMH) were predicted based on observable helices in the crystal structure of the Glycerol-3-phosphate transporter (GlpT, PDB code 1PW4 (20) ), another member of the MSF superfamily (supplemental Fig. S1 ) which can be used as a structural template for homology models (see section below). From this alignment it becomes obvious, that MCT family proteins share high sequence and most likely structural similarity, despite some regions of flexibility like the third intracellular loop (ICL3).
The high sequence similarity among MCT proteins suggested to us to propose a unifying numbering system for this protein subfamily. The rationale of this numbering scheme is adopted from the description by Ballesteros and Weinstein for family A G-protein-coupled receptors (GPCR) (21) . We use the numbering convention x.50 for the most conserved amino acids in each transmembrane helix (TMH) x. For example, the most highly conserved residue in TMH1 is defined as 1.50 and in TMH2 as 2.50 etc.. We suggest the following amino acids as highly conserved for all MCT ( Fig. 1) 12.50 (MCT8 F554). The crystal structure of the inward facing conformation of GlpT from Escherichia coli was used as a structural template for a MCT8 homology model (20) . The alignment between human MCT8 and GlpT amino acid sequences reveals a similarity score of 25.5% (supplemental Fig. S1 ). With small deviations, the helix dimensions observed in the GlpT crystal structure are applicable for human MCT8. The reliability of this structural template is supported by examples of modeling for other members of the MFS like GLUT1 (22) or MCT1 (23;24) . Helices in MCT8 comprise the following residues: TMH1 F166-L202, TMH2 Q212-T239, TMH3 C244-H260,  TMH4 R271-H296, TMH5 Q299-M326, TMH6  T336-T353, TMH7 G401-E429, TMH8 V435-L458, TMH9 I461-M477, TMH10 F484-L512,  TMH11 A521-G548, and TMH12 A553-D589. Gaps of missing residues in the loops of the template structure were closed by the 'Loop Search' tool implemented in Sybyl 7.35 (Tripos Inc., St. Louis, MO, USA). Comparison to loop conformations extracted from the PDB by the Super-Looper software (http://bioinformatics.charite.de/superlooper/index .php) were also performed to find superimposing loop-structures from the PDB as criteria for reliability. The quality and stability of the model were validated by checking the geometry using PROCHECK (25) .
Side-chains and loops of the homology model were subjected to conjugate gradient minimization (until converging at a termination gradient of 0.05 kcal/(mol*Å)) and molecular dynamics simulation (5 ns) by fixing the backbone H-bonds of the TMH. Finally the model was minimized without any constraints.
Structure images were produced using PyMOL software (DeLano WL, version 0.99, San Carlos, CA, USA (http://www.pymol.org)). 125 
RESULTS
Structural determinants of substrate molecules determined by competition with
I-T 3
The only substrates of MCT8 so far identified are iodothyronines (4) . A large number of iodothyronines and related molecules are available to probe structural determinants for transport by MCT8. The basic structure of thyroid hormones is the thyronine backbone carrying iodine atoms at one or several of four possible positions (Fig. 2A) . The thyroid produces mainly 3,3',5,5'-tetraiodo-L-thyronine (thyroxine, T 4 ) which can be converted by the action of iodothyronine deiodinases into any iodothyronine (26) . Moreover, thyronamines (TAM), decarboxylated iodothyronine derivatives, and iodothyroacetic acids are naturally occurring metabolites and exert biological and pharmacological effects (27;28) . We tested a total number of twenty-three iodothyronine derivatives for their interference with transport of the paradigmatic MCT8 substrate, T 3 . Among L-(iodo)thyronines, only T 4 , T 3 , rT 3 , and 3,3'-diiodothyronine (3,3'-T 2 ) competed with T 3 for transport (Fig. 2B) . We concluded that MCT8 requires for transport at least one iodine atom at the 3 positions in both aromatic rings. In addition, L-T 3 transport is inhibited only by Liodothyronines, while their D-isomers had no effect (Fig. 2C) . These results support and extend similar studies of rat Mct8 by Friesema (4). We then asked whether TAM, also compete with T 3 for transport by MCT8. In comparison with Liodothyronines, TAM lack the amino acid carboxyl group and the chiral center. Inhibition by a 1000-fold excess of any TAM was negligible with the single exception of 3-iodothyronamine (3-T 1 AM), an endogenous metabolite known to exert profound pharmacological effects (27;29) . But even at 10 µM, 3-T 1 AM achieved a maximal inhibition of only about 30% of T 3 uptake (Fig. 2D) (30) . Our next question was whether the amino group of the backbone represents an important structural determinant. In contrast to earlier findings with rat Mct8 (4), N-acetylation of iodothyronines is apparently tolerated by human MCT8, since NAc-T 3 and NAc-T 4 , both exhibited inhibitory effects similar to the non-acetylated compounds (Fig.  2E ). TRIAC and TETRAC were entirely devoid of inhibitory potential in the competition assay (Fig.  2E) . Our conclusions regarding substrate recognition were supported by the lack of inhibition by 3,5-diiodo-thyropropionic acid (DITPA, see Fig 2E) , a thyromimetic compound which was used to pharmacologically circumvent the transport deficiency in Mct8-deficient mice (31) . Unlike the closely related MCT10, MCT8 does not accept aromatic amino acids (Fig. 2F ). Finally, we tested polyphenolic flavonoids F21388 and naringenin for inhibition of T 3 transport. These compounds were previously shown to bind to transthyretin and compete for T 4 binding. Both flavonoids were inactive in this uptake assay in contrast to the known MCT8 inhibitor, bromosulphtalein (BSP, Fig. 2G) (4) .
Measuring the uptake of MCT8 substrates with LC-MS/MS
Competition assays are an easy and common way to determine structural determinants for receptor binding or transport. However, this type of experiments represents an indirect approach. We took advantage of our LC-MS/MS assays for iodothyronines and TAM (17;18) and directly measured uptake of unlabelled ligands into MCT8-transfected MDCK1 cells. In a first step, we validated the LC-MS/MS method in direct comparison with the established 125 I-T 3 uptake assay ( Fig. 3A and B) . The K M values determined by both methods, 4.7 µM and 7.5 µM, are within the range reported for rat, 4-8 µM (4). We then tested T 3 AM and TRIAC. Even at 50 µM, both compounds were not transported by MCT8 (Fig.  3C) . Thus, the direct assay supports that MCT8 requires the intact L-amino acid backbone for substrate recognition.
Two charged amino acids are spatially located at the potential substrate transport channel We were interested in the identification of amino acids in MCT8, which are involved in substrate recognition. Structure-function analysis of the substrate suggested a requirement for both amino and carboxylic functional groups. Therefore, we focussed on charged amino acids located in the transmembrane helices. The MCT sequence alignment revealed that all MCTs carry a conserved arginine in TMH8 (R445, position 8.50). In MCT1, the corresponding amino acid (R306) is described to be essential for transporter function (23) . We built a homology model for MCT8 based on the X-ray structure of GlpT (Fig.  4A) . Our model is in a conformation open to the intracellular side (Fig. 4B ). In this model the charged side chain R445 points into the interior space between the transmembrane helices.
Moreover, R445 protrudes into a solvent filled cavity, which we presume is the substrate channel (Fig. 4B) . This arginine likely interacts within the interior region of the transporter with a negative charge from the substrate. The MCT8 model further suggests a salt bridge between R445 and D498 (TMH10). Thus, both charged residues might be involved in essential helix interactions or in substrate recognition.
Mutations in R445 and D498 lead to total loss of transport activity
In order to test the significance of the two charged amino acids, R445 and D498, for substrate transport, we replaced both amino acids with alanine, established stable cell clones and tested their activity. Alanine replacement removes charges while retaining the propensity of a peptide to form helices. Both mutants were expressed at lower levels than wildtype, but were exposed to the plasma membrane as shown by surface biotinylation (Fig. 5A) . Strikingly, both mutants entirely lacked any 125 I-T 3 uptake activity (Fig.  5B) . If the functional role of these charged amino acids relied solely on interaction with the amino acid backbone of the iodothyronine substrate, alanine mutants should accept T 3 AM or TRIAC at least at high concentration. We tested this hypothesis directly using the LC-MS/MS assay. Both alanine mutations entirely abrogated transport of T 3 and the mutant MCT8 did neither accept TRIAC nor T 3 AM (Fig. 5C ). This finding is compatible with the assumption that an essential salt-bridge between basic R445 and acidic D498 may be formed during the transport cycle.
DISCUSSION
As a first step to gain insight into structural features, substrate interaction, and transport mechanism of thyroid hormone transporters, we systematically delineated the conserved structural elements in MCT8 substrates and tried to identify amino acids in MCT8 potentially interacting with substrate. A homology model for MCT8 was built based on the structure of GlpT, a bacterial Glycerol-3-phosphate transporter (20) . Combining modelling and biochemical approaches, we identified two essential charged amino acids in TMH8 and TMH10 located in close proximity to the presumed substrate transport channel.
Substrate determinants required for recognition by MCT8
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Using 23 iodothyronine and related compounds, we systematically investigated their structure function relationships to extract key features of MCT8 substrates. Unlike MCT10 (4;5), MCT8 does not transport aromatic amino acids, suggesting specificity for the thyronine structure. Moreover, human MCT8 is sensitive to the number and distribution of iodine atoms attached to the thyronine backbone. Our data support and extend earlier work done in Xenopus oocytes (4) and show that MCT8 substrates have to carry at least an iodine atom in the 3 positions of both aromatic rings. In addition, an L-amino acid moiety is essential. In contrast to the findings on rat Mct8 expressed in Xenopus oocytes (4), human MCT8 expressed in MDCK1 cells tolerated N-acetylation of iodothyronines, and was not inhibited by D-isomers and TRIAC. Neither naringenin nor F21388 interfered with T 3 transport by MCT8. Hence, MCT8 has higher specificity for iodothyronines than type I-deiodinase (32-34), transthyretin (32) , and T 3 -receptors (35;36) .
Amino acids in MCT8 involved in both substrate recognition and transport
Our alignment of MCT family amino acid sequences revealed R445 (position 8.50) as conserved among all MCT family proteins (Fig.  1 ). This high conservation indicates an important and specific function for this amino acid and indeed, in our homology model, R445 protrudes into a central cavity in the protein in between the helices (Fig. 4B) , which we assume is representing the substrate channel in accordance with the GlpT structure (20) . This channel assignment is in agreement with the hypothesis that cavities within membrane gates are encircled by polar amino acids (37) . Moreover, this is in agreement with recent results on MCT1, where the involvement of arginine R306 (TMH8, position 8.50) for transport activity was found, which corresponds to R445 (TMH8. position 8.50) in MCT8. In addition, on MCT1 the negatively charged residue D302 at the same TMH8 (position 8.46) was also identified to contribute in the transport mechanism (23;24;38) . Guided by our MCT8 model we found on MCT8 a further charged amino acid, D498 (TMH10, position 10.49), which may cooperate with R445 in positioning the invariate L-amino acid moiety of the substrate. Consistent with an assumed substrate interaction is our observation that D498 is only conserved among MCT8 and MCT10 transporters (Fig. 1) , the only MCT family members with known amino acid/iodothyronine substrates. Mutation of either amino acid to alanine entirely abrogates T 3 transport by mutant MCT8, although the mutants were exposed to the plasma membrane.
We speculate that both amino acids may bear a function beyond substrate binding. Indeed, our model suggests a salt bridge between both side-chains, which may form at least transiently during the transport cycle. Binding of substrate would cause modification of the charged interaction and in consequence break the salt bridge (R445-D498), which is possibly specific for the inward facing conformation of MCT8. In this conformation, R445 establishes simultaneously a H-bond with the backbone of TMH7 and thus constrains a triad of TMH7, TMH8 and TMH10. Destabilization at the interfaces between these helices should facilitate the assumed relative rotation of helices to each other as proposed for GlpT (20) . We suggest, therefore, a dual functionality for R445 and D498 involving both substrate recognition and the molecular mechanics of transport. We did not create an R445D/D498R double mutant to test the potential salt bridge, since our model predicted that arginine at position 498 would block the presumed binding site, while an aspartate at position 445 would be to short to reach the solvent-filled channel.
We have mapped known pathogenic missense mutations in MCT8 (Tab. 2) onto our homology model and observed that some occurred around the region surrounding R445, D498, and the presumed substrate channel (Fig. 6 ), e.g. at D453 (TMH8, position 8.58). In the recent review of Friesema et al. (13) , which was published while our work was in progress, two novel pathogenic mutations were mentioned, which are particularly pertinent to our discussion here: R445C and H192R. Both mutations have deleterious effects on T 3 transport in patients (39) . According to our structural model, H192 (TMH1, position 1.66) corresponds to the substrate-binding sensitive R45 in the GlpT (20;40) . Interestingly, in the crystal structure of the thyroid hormone receptor (PDB code 3GWS (41)), a positively charged amino acid is mandatory and a histidine in a T 3 binding pocket contributes to iodothyronine binding. We therefore conclude that replacement of H192 with arginine in MCT8 should potentially interfere with binding of substrate. The pathogenic substitution R445C might lead to a loss of ionic interaction(s) consistent with our proposed mechanism for the R445A mutant. We conclude that our model can serve as a basis for further investigations into structure-function relationships in MCT8 and may further allow the rational interpretation and prediction of structural changes caused by pathogenic mutations. (Fig. 6 ) to reveal insights into their spatial neighborhood to residues R445 and D498. The mutations are helpful to evaluate function of wildtype amino acids, also with respect to their potential contact partners. Finally the combination of such sequence-structure-(mal)function relationships is a reliable procedure to identify and to describe hot-spots of transport mechanisms. . D498 of MCT8 is red boxed and can also be found in MCT10, another T 3 transporting MCT family member. Boxed are the potential dimensions of the transmembrane helices (TMHs) based on the X-ray structure of an E.coli Glycerol-3-phosphate transporter, another member of the major facilitator superfamily. We suggest a unifying numbering system for the MCTs indicated by the italic numbers above each TMH-box. This position identifier scheme uses a highly conserved residue in each transmembrane helix as a common reference for all members of the MCT family. For example, the highly conserved tryptophan in TMH1 is defined as 1.50 and the highly conserved proline from TMH2 is defined as 2.50. The first number is related to the particular helix, the second number after the dot determines the specific position in relation to the conserved residue. This procedure might be helpful to compare insights from different MCT species. For specific comparison between MCT subtypes we provide amino acid numbering for each MCT in the right column. Crystal structure of the Glycerol-3-phosphate transporter (PDB code 1PW4, white backbone), another member of the major facilitator superfamily, which was used as a structural template. Two arginines and a histidine (blue sticks, dotted circle, GlpT amino acids R45-TMH1, H165-TMH5, H169-TMH5, R269-TMH7) are known to be related to Glycerol-3-phosphate (G3P) binding which is mediated by the phosphate moiety of G3P (20) . This binding site is located in the middle of the transmembrane region of the GlpT and is part of a central cavity which represents the presumed substrate transport channel. B. Lengths of specific loops and helices may vary in detail between the MCT8 model compared to the crystal structure of GlpT (A), but the overall topology especially in the transmembrane region is assumed to be similar. The two charged amino acids R445 in blue (TMH8) and D498 in red (TMH10) are located in the central transmembrane part of the MCT8. In the top-view with clipped extracellular loops the arrangement of the helices to each other is visualized and shows TMH8 and TMH10 in close neigborhood where these charged residues are located. Both amino acids are in close spatial distance and they are flanking the potential channel for substrate-transport (light blue circle in the top view). This spatial region superimposes with the known binding region for G3P in the GlpT (Fig. 4A) . Therefore orientations of these residues are predestined for both helix-justification and/or substrate binding. Arginine 445 and aspartate 498 are suggested to interact via H-bond (dotted line). Mapping of pathogenic side-chain substitutions onto the MCT8 homology model. We conclude from our MCT8 homology model with highlighted amino acid positions (green) of reported pathogenic side-chain substitutions (Tab. 2) that the spatial region surrounding D498 and R445 is characterized by high sensitivity for transport. The close spatial distances to amino acids like D453 or H192, which are also located at the potential transport-cavity are remarkable. However, pathogenic mutations are identified in most of the helices and some mutations may cause protein-folding defects. Figure 1 by guest, on July 19, 2010 
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